Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754635 | 1.00 | KRAS (0.53) | KRAS | |
| SCHEMBL22330848 | 0.92 | KRAS (0.49) | KRAS | |
| SCHEMBL29754580 | 0.92 | KRAS (0.52) | KRAS | |
| SCHEMBL29754491 | 0.92 | KRAS (0.49) | KRAS | |
| SCHEMBL22330888 | 0.92 | KRAS (0.52) | KRAS | |
| SCHEMBL22330820 | 0.91 | KRAS (0.46) | KRAS | |
| SCHEMBL29754485 | 0.91 | KRAS (0.46) | KRAS | |
| SCHEMBL22049228 | 0.91 | KRAS (0.53) | KRAS | |
| SCHEMBL29754515 | 0.91 | KRAS (0.53) | KRAS | |
| SCHEMBL22349088 | 0.91 | KRAS (0.47) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-11377441-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210024501-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC | 2021-01-28 | — | — | US | disclosed |
| US-10745385-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745385-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2020-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024501-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | KRAS 1/4885 |
| US-11377441-B2 | Covalent inhibitors of KRAS | KRAS, NRAS, HRAS | KRAS 1/4885 |
| US-10745385-B2 | Covalent inhibitors of KRAS | KRAS, NRAS, HRAS | KRAS 1/4885 |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.